ArticleLasers in medical science2025
Liposome-encapsulated bacteriochlorin: tumor cell inactivation using photodynamic therapy.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sorafenib-loaded porphyrin-phospholipid liposomes for enhanced chemophototherapy in hepatocellular carcinoma.RSC advances · 2026Article
- Cationic Bacteriochlorin in the photodynamic inactivation of microorganisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Antitumor effects of a novel glucose-conjugated bacteriochlorin for photodynamic therapy.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Photodynamic Therapy (PDT) employs light and non-toxic components, including a photosensitizer (PS) and oxygen, to induce cellular effects and target cancer cells. Bacteriochlorin (Bch), a PS absorbing longer wavelengths, offers deeper tissue penetration, broadening PDT's therapeutic reach. A liposomal formulation (LF) was developed to improve solubility, stability, bioavailability, and enable controlled, targeted drug release to enhance Bch's effectiveness. The present study aims to describe a new third generation of low-cost Bch, reducing the required dose for cancer cell death. Researchers compared the photodynamic activity of Bch in its free form and as an LF, evaluating its efficiency and therapeutic potential in vitro. Bch was obtained from bacterial precursors via extraction and transesterification. LF was produced using the film hydration method, a low-cost method without the need for expensive equipment. Absorbance and cell viability (MTT assay) data were analyzed statistically (ANOVA and Tukey test, 95% confidence interval). Results showed LF significantly outperformed free Bch in all tested cell lines. LF exhibited 140 times higher potency in MIA PaCa-2 cells (IC
Indexed as
Identifiers
40358777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.